Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial

Table 1 Characteristics of Eligible Patient Population, Study vs. Control Sites

		STUDY (n = 16,584)	CONTROL (n = 13,423)	P-Value
Mean Age (yrs)		61	60	<.0001
% Female		49.9	51.8	<.0001
Race/Ethnicity (%)
	Asian/PI	9.0	12.3	<.0001
	Black	6.1	16.2	<.0001
	Hispanic	9.8	12.6	<.0001
	Native American	1.3	1.3	0.97
	White	62.0	44.4	<.0001
	Other/Multiple	2.9	2.2	<.0001
	Missing Race	8.9	11.0	<.0001
Comorbidities
	Mean Number of Comorbidities*	1.23	1.25	0.01
	Has Diabetes (%)	77.5	80.4	<.0001
	Current Smoker (%)	8.9	9.0	0.77
Mean Risk Factor Values at Baseline**
	Systolic Blood Pressure (mm Hg)	131	132	0.18
	LDL-cholesterol (mg/dL)	100	98	<0.001
	Hemoglobin A1c (%)	7.3	7.3	0.13
Mean # Medication Classes, Baseline
	Blood Pressure Medications	1.74	1.82	<.0001
	Diabetes Medications	1.22	1.23	0.19
	Dyslipidemia Medications	0.70	0.70	0.35
On Max Med Therapy at Baseline (%)
	Simvastatin/Atorvastatin 80 mg	12.3	13.8	<.0001
	3 or more Blood Pressure Meds	27.8	31.0	<.0001
	Insulin, if has diabetes	20.0	20.5	0.38
Baseline control rates (%) Entire PHASE Populations - by priority level
Priority 1: SBP <140 mmHg		83.5	81.8
Priority 4: SBP <130 mmHg		61.1	60.7
Priority 2: LDL-c <130 mg/dL		90.2	90.2
Priority 5: LDL-c <100 mg/dL		71.8	71.7
Priority 3: A1c <9%		90.3	90.9
Priority 6: A1c <7%		60.5	60.0

*Comorbidity count based on whether patient is flagged in the Population Management Tool as being in these populations: abdominal aortic aneurism, coronary artery disease, chronic kidney disease, diabetes, peripheral artery disease, and cerebrovascular disease.

ISSN: 1472-6963